Compare SMID & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | NVCT |
|---|---|---|
| Founded | 1960 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.7M | 167.0M |
| IPO Year | 1995 | 2022 |
| Metric | SMID | NVCT |
|---|---|---|
| Price | $34.58 | $6.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | 10.3K | ★ 90.0K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $88,866,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.69 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $25.13 | $4.44 |
| 52 Week High | $51.96 | $11.52 |
| Indicator | SMID | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 54.35 |
| Support Level | $32.33 | $5.85 |
| Resistance Level | $35.56 | $6.21 |
| Average True Range (ATR) | 2.22 | 0.28 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 41.40 | 70.91 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.